PSMA/FAPI双特异性示踪剂¹⁸F-ALF-NOTA-PSFA-1与¹⁸F-FDG PET/CT在骨原发透明细胞肉瘤检测中的比较
一例43岁男性左髋痛患者,增强CT示左侧髂骨及骶骨溶骨性破坏伴软组织延伸,提示骨肿瘤。¹⁸F-FDG PET/CT仅见髂骨、骶骨及右腓骨病灶轻度或无FDG摄取,而PSMA/FAPI双特异性示踪剂¹⁸F-ALF-NOTA-PSFA-1 PET/CT上这些病灶呈浓密或增高摄取。提示¹⁸F-ALF-NOTA-PSFA-1 PET/CT对肉瘤检测有潜力,并可能支持PSMA/FAPI双特异性靶向受体放射性核素治疗的发展。
要点
- 骨原发透明细胞肉瘤在¹⁸F-FDG PET/CT上可表现为轻度或无摄取。
- PSMA/FAPI双特异性示踪剂¹⁸F-ALF-NOTA-PSFA-1在病灶中呈浓密或增高摄取。
- 该示踪剂可能支持PSMA/FAPI双特异性靶向受体放射性核素治疗的开发。
核心结论
- ¹⁸F-ALF-NOTA-PSFA-1 PET/CT对肉瘤检测有相当潜力,并可能支持PSMA/FAPI双特异性靶向受体放射性核素治疗的发展。
研究设计与样本
- 单例43岁男性病例报告,因左髋痛就诊,行增强CT、¹⁸F-FDG PET/CT及¹⁸F-ALF-NOTA-PSFA-1 PET/CT检查。
主要发现
- 增强CT示左侧髂骨及骶骨溶骨性破坏伴软组织延伸,提示骨肿瘤。
- ¹⁸F-FDG PET/CT示髂骨、骶骨及右腓骨病灶仅轻度或无FDG摄取。
- ¹⁸F-ALF-NOTA-PSFA-1 PET/CT示上述病灶浓密或增高摄取。
临床怎么用
- 对FDG摄取不高但仍怀疑骨肉瘤的病灶,可考虑PSMA/FAPI双特异性示踪剂PET/CT辅助检测。
局限性
- 仅为单例病例报告,结论需更大样本研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 43-year-old man presented with left hip pain. Contrast-enhanced CT demonstrated lytic destruction of the left ilium and sacrum with associated soft-tissue extension, suggestive of a bone tumor. Subsequent ¹⁸F-FDG PET/CT revealed only mild or no FDG avidity in lesions involving the ilium, sacrum, and right fibula. In contrast, these lesions demonstrated intense or elevated uptake on PSMA/FAPI bispecific tracer ¹⁸F-ALF-NOTA-PSFA-1 PET/CT. These observations indicate that ¹⁸F-ALF-NOTA-PSFA-1 PET/CT holds considerable potential for sarcoma detection and may support the development of PSMA/FAPI bispecific targeted receptor radionuclide therapy.
引用
- Wu J, Gao H, He L, et al. Comparison of PSMA/FAPI Bispecific Tracer ¹⁸F-ALF-NOTA-PSFA-1 and ¹⁸F-FDG PET/CT in the Detection of Primary Clear Cell Sarcoma of Bone. Clin Nucl Med. 2026. PMID: 41941244. doi:10.1097/RLU.0000000000006421
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。